Plain-English translation of NCT05370144 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to treating esophageal and gastroesophageal junction cancer. You would receive two chemotherapy drugs—carboplatin and paclitaxel—by IV infusion once a week for 5 weeks, combined with an accelerated course of radiation therapy (delivered in just 5 sessions over one week). After completing this combined treatment, you would have surgery to remove the affected part of your esophagus.
Currently, patients with this type of cancer typically receive chemotherapy and radiation over a longer period before surgery. This trial is testing whether delivering the radiation more intensively over a shorter time might be just as effective—or even better—while potentially reducing side effects and getting patients to surgery faster.
You likely qualify if…
You likely don't qualify if…
You would come to the hospital or clinic once a week for 5 weeks to receive the chemotherapy infusions. During week 3, 4, or 5 of your chemotherapy, you would receive radiation therapy—a short course of 5 daily sessions. Your doctors would check you weekly during treatment and every two weeks afterward for side effects. About 6 weeks after finishing chemotherapy and radiation, you would have imaging scans (PET/CT), and then surgery 6 to 12 weeks later to remove the affected part of your esophagus. You would have follow-up visits with your cancer doctors to monitor your recovery.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Canada